- Home
- TORO vs BOLD Comparison
TORO vs BOLD Comparison
Compare TORO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- BOLD
- Stock Information
- Founded
- TORO 2022
- BOLD 2018
- Country
- TORO Cyprus
- BOLD United States
- Employees
- TORO N/A
- BOLD N/A
- Industry
- TORO Marine Transportation
- BOLD
- Sector
- TORO Consumer Discretionary
- BOLD
- Exchange
- TORO Nasdaq
- BOLD Nasdaq
- Market Cap
- TORO 36.7M
- BOLD 30.3M
- IPO Year
- TORO N/A
- BOLD 2024
- Fundamental
- Price
- TORO $1.87
- BOLD $1.13
- Analyst Decision
- TORO
- BOLD Buy
- Analyst Count
- TORO 0
- BOLD 3
- Target Price
- TORO N/A
- BOLD $4.00
- AVG Volume (30 Days)
- TORO 33.4K
- BOLD 79.0K
- Earning Date
- TORO 06-10-2025
- BOLD 05-09-2025
- Dividend Yield
- TORO N/A
- BOLD N/A
- EPS Growth
- TORO N/A
- BOLD N/A
- EPS
- TORO 1.09
- BOLD N/A
- Revenue
- TORO $22,394,283.00
- BOLD N/A
- Revenue This Year
- TORO N/A
- BOLD N/A
- Revenue Next Year
- TORO N/A
- BOLD N/A
- P/E Ratio
- TORO $1.72
- BOLD N/A
- Revenue Growth
- TORO 0.40
- BOLD N/A
- 52 Week Low
- TORO $1.70
- BOLD $1.06
- 52 Week High
- TORO $4.71
- BOLD $10.13
- Technical
- Relative Strength Index (RSI)
- TORO 45.71
- BOLD N/A
- Support Level
- TORO $1.80
- BOLD N/A
- Resistance Level
- TORO $1.92
- BOLD N/A
- Average True Range (ATR)
- TORO 0.09
- BOLD 0.00
- MACD
- TORO 0.01
- BOLD 0.00
- Stochastic Oscillator
- TORO 33.90
- BOLD 0.00
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.